Update (June 24, 2026): SDMA Detected Feline CKD a Mean of 17 Months Before Creatinine in Longitudinal Study

Bottom line.

• Serum SDMA (symmetric dimethylarginine) became elevated before serum creatinine in 17 of 21 cats with progressive CKD in a longitudinal study; the mean lead time was 17.0 months (range 1.5–48 months).¹
• SDMA had higher sensitivity (100%) than creatinine (17%) for detecting CKD in that study, though at lower specificity (91%) compared with creatinine (100%), consistent with the trade-off expected when using a more sensitive marker.¹
• Unlike creatinine, SDMA is unaffected by lean body mass — an important practical advantage in cats, which commonly lose muscle condition as CKD advances.¹
• SDMA is now incorporated into the IRIS CKD staging system: SDMA > 14 μg/dL persistently elevated can indicate CKD and prompt staging at Stage 1 or 2 even before creatinine is azotaemic.²
• This is a clinician-facing evidence summary. It is not a dosing protocol; use SDMA results in context with clinical examination, UPC, urine concentrating ability and other patient factors.

Biomarker overview

• Molecule: Symmetric dimethylarginine (SDMA) — a methylated arginine derivative released from nucleated cells during protein degradation, freely filtered at the glomerulus, not tubularly reabsorbed or secreted, and not metabolised extra-renally.¹
• GFR surrogate mechanism: SDMA elimination is dependent on glomerular filtration rate (GFR), so blood SDMA rises as GFR falls; production rate is stable and independent of muscle mass.¹
• Key advantage vs creatinine: Rises earlier (mean 17 months before creatinine in cats); unaffected by lean body mass, diet, or non-renal chromogen interference.¹
• Current assay: The SDMA assay referenced in the IRIS CKD staging system is standardised to the IDEXX Laboratories proprietary method; the reference interval upper limit is 14 μg/dL for cats.²

Questions about SDMA interpretation in a specific patient?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific biomarker context, IRIS staging guidance, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Hall et al. 2014 — longitudinal study in cats with CKD

The foundational feline SDMA study by Hall et al. compared serum SDMA and serum creatinine concentrations as biomarkers of renal function in cats with CKD.¹ In 21 cats followed longitudinally, SDMA became elevated before creatinine in 17 of 21 cats (81%), with a mean lead time of 17.0 months (range 1.5–48 months).¹ Both SDMA (r = −0.79) and creatinine (r = −0.77) were significantly and comparably correlated with GFR (both P < .0001), confirming that SDMA reflects glomerular filtration comparably to creatinine as a point measure. However, in detecting CKD earlier in the course of disease, SDMA's sensitivity was 100% versus 17% for creatinine, with SDMA specificity at 91% and creatinine specificity at 100%.¹ The authors concluded that SDMA allows earlier detection of CKD in cats compared with creatinine, which may be desirable for initiating renoprotective interventions that slow progression.

Limitations of SDMA

SDMA is generally not influenced by muscle mass, making it especially useful in cachectic or aged cats with reduced muscle mass where creatinine may be misleadingly low. However, SDMA can be falsely elevated in hyperthyroid cats (as thyroid hormones affect production and GFR simultaneously), and haemolysis interferes with the IDEXX SDMA assay producing falsely low results. Breed effects are documented: Birman cats have a wider reference interval (3.4–19.2 μg/dL), and species- or breed-specific considerations should be applied.²

IRIS integration

The IRIS CKD staging framework now uses SDMA alongside creatinine for staging.² Persistently elevated SDMA > 14 μg/dL (confirmed on repeat testing approximately 2 weeks apart) is sufficient to diagnose CKD and assign IRIS Stage 1 (SDMA 15–17 μg/dL) or Stage 2 (SDMA > 17 μg/dL) even when creatinine remains within the reference interval. When SDMA and creatinine give discordant stage assignments, IRIS recommends applying the higher stage as a precautionary approach. Serial tracking of both markers in parallel improves sensitivity for detecting progression.²

How this fits clinical practice

SDMA is best used as part of a paired creatinine + SDMA panel rather than in isolation, and results must be interpreted in the context of clinical examination, urine specific gravity, UPC, blood pressure and patient body condition.^1,2 The 17-month average lead time before creatinine elevation in the Hall et al. cohort represents a clinically meaningful window during which renoprotective interventions — dietary phosphate restriction, antiproteinuric agents, blood pressure control — could theoretically be initiated earlier. In practice, SDMA should be repeated 2–4 weeks after an initial elevation before staging, and non-renal causes of elevated SDMA (hyperthyroidism, hypoadrenocorticism in dogs) should be considered. Do not make treatment decisions on a single SDMA result alone.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE. 2014. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. J Vet Intern Med 28(6):1676-83. https://pubmed.ncbi.nlm.nih.gov/25231385/
2. Elliott J, White J. IRIS Staging System. International Renal Interest Society. 2025 (updated). https://www.iris-kidney.com/iris-staging-system

Changelog

• 2026-06-24: First published.